Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.

Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.

2.

Thrombin receptor expression is upregulated in prostate cancer.

Kaushal V, Kohli M, Dennis RA, Siegel ER, Chiles WW, Mukunyadzi P.

Prostate. 2006 Feb 15;66(3):273-82.

PMID:
16245281
3.

Regulation of prostate cancer progression by galectin-3.

Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A.

Am J Pathol. 2009 Apr;174(4):1515-23. doi: 10.2353/ajpath.2009.080816. Epub 2009 Mar 12.

4.
5.

Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.

Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, Croci MC, Shipp MA, Mesri EA, Albini A, Rabinovich GA.

J Exp Med. 2012 Oct 22;209(11):1985-2000. doi: 10.1084/jem.20111665. Epub 2012 Oct 1.

6.

Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.

Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J, Kuczyk MA.

Prostate. 2008 Jan 1;68(1):72-7.

PMID:
18008332
7.

Varied expression and localization of multiple galectins in different cancer cell lines.

Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS, Rao US.

Oncol Rep. 2008 Mar;19(3):587-94.

PMID:
18288388
8.

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.

Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW.

Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15975-80. Epub 2006 Oct 16.

9.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.

Cancer Treat Rev. 2014 Mar;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007. Epub 2013 Aug 1. Review.

PMID:
23953240
10.

A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.

Agell L, Hernández S, Nonell L, Lorenzo M, Puigdecanet E, de Muga S, Juanpere N, Bermudo R, Fernández PL, Lorente JA, Serrano S, Lloreta J.

Am J Pathol. 2012 Nov;181(5):1585-94. doi: 10.1016/j.ajpath.2012.08.005. Erratum in: Am J Pathol. 2013 Feb;182(2):610.

PMID:
23083832
11.

Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein LE, Härkönen P, Persson JL.

J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36. doi: 10.1093/jnci/djn214. Epub 2008 Jul 8.

12.

Decreased galectin-3 expression in prostate cancer.

Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR.

Prostate. 2000 Jul 1;44(2):118-23.

PMID:
10881021
13.

Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.

Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, Sun KH.

Clin Cancer Res. 2012 Aug 1;18(15):4037-47. Epub 2012 Jun 13.

14.

Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer.

Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R.

Urol Res. 1999 Oct;27(5):362-7.

PMID:
10550525
15.

Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.

Roda O, Ortiz-Zapater E, Martínez-Bosch N, Gutiérrez-Gallego R, Vila-Perelló M, Ampurdanés C, Gabius HJ, André S, Andreu D, Real FX, Navarro P.

Gastroenterology. 2009 Apr;136(4):1379-90, e1-5. doi: 10.1053/j.gastro.2008.12.039. Epub 2008 Dec 13.

PMID:
19171142
16.

MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.

Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK.

Int J Oncol. 2002 Sep;21(3):469-75.

PMID:
12168088
18.

Delineating the "galectin signature" of the tumor microenvironment.

Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA.

Oncoimmunology. 2013 Apr 1;2(4):e23565.

19.
20.

Evolution of the androgen receptor pathway during progression of prostate cancer.

Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G.

Cancer Res. 2006 May 15;66(10):5012-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk